AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shot up 1.8% on Monday . The stock traded as high as $3.49 and last traded at $3.44, with a volume of 53,732 shares. The stock had previously closed at $3.38.

Several brokerages recently weighed in on ACRX. RBC Capital Markets reaffirmed a “positive” rating and set a $6.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, August 16th. Jefferies Group reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Wednesday, August 10th. Stifel Nicolaus downgraded shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. HC Wainwright reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st. Finally, Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, July 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. AcelRx Pharmaceuticals currently has an average rating of “Hold” and an average price target of $7.30.

The firm has a 50 day moving average of $3.27 and a 200 day moving average of $3.34. The firm’s market cap is $160.86 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. The company had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $2.17 million. On average, analysts predict that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.